GH Research PLC
GHRS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GHRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GHRS
GH Research PLC (GHRS) is a clinical-stage biopharmaceutical company focused on developing novel therapies, including GH001 and GH002, for psychiatric and neurological disorders, with no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 941 clinical trials · 153 catalysts for GH Research PLC.
GH Research PLC (GHRS) is a clinical-stage biopharmaceutical company focused on developing novel therapies, including GH001 and GH002, for psychiatric and neurological disorders, with no approved products or revenue to date.
- GH Research is a clinical-stage biopharmaceutical company with two product candidates, GH001 and GH002, in development [sec · filed 2026-03-05].
- The company has incurred significant losses since inception and expects losses to increase as it advances clinical trials and regulatory activities [sec · filed 2026-03-05].
- As of December 31, 2025, GH Research reported cash and equivalents of $246.3 million, net income of -$14.1 million, and shareholders' equity of $249.8 million [sec].
- GH Research has no products approved for commercial sale and has not generated any revenue to date [sec · filed 2026-03-05].
- The company's completed clinical trials have been conducted only in Europe, and it has not initiated or completed a pivotal clinical trial [sec · filed 2026-03-05].
What works
- GH Research has a cash position of $246.3 million as of December 31, 2025, which may support ongoing development activities [sec].
- The company is developing proprietary medical devices, such as an aerosol delivery device for GH001, which could provide a competitive advantage if successful [sec · filed 2026-03-05].
- GH Research has multiple upcoming clinical trial starts scheduled for 2026, including Phase 1 and Phase 2 studies across various indications, indicating active pipeline advancement [upcoming catalysts].
What to weigh
- GH Research is a clinical-stage company with no approved products or revenue, and it has incurred significant losses since inception [sec · filed 2026-03-05].
- The company's clinical trials have been small with short follow-up, which may make results less reliable and hinder regulatory approval [sec · filed 2026-03-05].
- GH Research relies on the success of only two product candidates (GH001 and GH002), and failure of either could materially impact the business [sec · filed 2026-03-05].
- The company expects expenses to increase substantially as it expands clinical trials and manufacturing, requiring additional capital that may not be available [sec · filed 2026-03-05].
From the filings
Quoted directly from source documents.
GH Research has no approved products and no revenue.
“We have no products approved for commercial sale and have not generated any revenue to date”
SEC filings · March 5, 2026
The company has incurred significant losses and expects them to increase.
“We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We expect that we will continue to incur significant losses for the foreseeable future.”
SEC filings · March 5, 2026
Clinical trials have been small with short follow-up, potentially reducing reliability.
“Since the number of patients included in our clinical trials is small and the follow-up is short, the results from such clinical trials may be less reliable than results achieved in larger clinical trials with longer follow-up”
SEC filings · March 5, 2026
GH Research has not initiated a pivotal clinical trial.
“we have not initiated nor completed a pivotal clinical trial, obtained marketing approval for any product candidates”
SEC filings · March 5, 2026
Catalyst timeline
- 2026-08-30 · Phase 1 Start: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics an — Initiation of a Phase 1 trial to assess safety and pharmacokinetics of an undisclosed candidate.
- 2026-09-01 · Phase 2 Start: Ultra-low Dose Transdermal Estradiol Therapy in Prepubertal Girls With Turner Syndrome and Primary O — Phase 2 trial start for ultra-low dose transdermal estradiol in Turner syndrome.
- 2026-09-01 · Phase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled — Phase 2 trial start for novel low back pain interventions in veterans.
- 2026-09-23 · Phase 2 Start: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluat — Phase 2b dose-ranging trial start for an undisclosed candidate.
- 2026-10-01 · Phase 2 Start: A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer — Phase 1b/2 trial start for capivasertib plus immunotherapy in bladder cancer.
- 2026-10-01 · Phase 2 Start: A Randomized Trial of Omega-3 Dietary Supplementation, Anti Demodex Eyelid Cleanser, and Standard Ey — Phase 2 trial start for omega-3 supplementation and eyelid cleanser in eye health.
- 2026-10-01 · Phase 1 Start: Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (PRECISE) — Phase 1 trial start for radioembolisation in recurrent glioma.
- 2026-10-01 · Phase 2 Start: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD — Phase 2 trial start for SGLT2 inhibition in veterans with chronic kidney disease.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — GH Research has no products approved for commercial sale and has not generated any revenue, relying entirely on future development success [sec · filed 2026-03-05].
- Reliance on two product candidates — The company's pipeline is limited to GH001 and GH002; failure of either could severely impact the business [sec · filed 2026-03-05].
- Need for additional capital — The company expects expenses to increase and may need additional financing, which may not be available on favorable terms [sec · filed 2026-03-05].
- Limited clinical data reliability — Completed trials have small patient numbers and short follow-up, potentially reducing statistical significance and regulatory confidence [sec · filed 2026-03-05].
What to watch
- Initiation of Phase 1 and Phase 2 clinical trials scheduled for 2026, including studies for GH001 and GH002 [upcoming catalysts].
- Regulatory filings and approvals from the FDA, EMA, or other authorities for GH001 and GH002 [sec · filed 2026-03-05].
- Progress in technical development and expansion of external manufacturing capabilities for GH001 and GH002 [sec · filed 2026-03-05].
- Ability to secure additional financing to support ongoing and expanded clinical programs [sec · filed 2026-03-05].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run GH Research PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GH Research PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
46.3 months
D/E 0.03
No tracked pipeline phase
No tracked pipeline candidates
153 upcoming
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
52
Total value held
$619.4M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 10,763,288 | $151.3M |
| bvf inc/il | 8,650,158 | $121.6M |
| ra capital management, l.p. | 7,676,697 | $107.9M |
| rtw investments, lp | 5,933,815 | $83.4M |
| fmr llc | 5,136,045 | $72.2M |
| toronto dominion bank | 1,397,873 | $19.7M |
| millennium management llc | 937,898 | $13.2M |
| 5am venture management, llc | 572,665 | $8.1M |
| blackrock, inc. | 455,618 | $6.4M |
| ubs group ag | 412,416 | $5.8M |
Showing top 10 of 52 institutional holders of GH Research PLC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.6%
- Days to cover
- 14.8
- Shares short
- 2,150,354
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GHRS short interestFrequently asked questions
What is the AI investment thesis for GH Research PLC?
GH Research PLC (GHRS) is a clinical-stage biopharmaceutical company focused on developing novel therapies, including GH001 and GH002, for psychiatric and neurological disorders, with no approved products or revenue to date.
What is GH Research PLC's next catalyst?
GH Research PLC's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics an" — expected August 30, 2026.
Who is the CEO of GH Research PLC?
Dr. Velichka Valcheva M.D., M.Sc. is the chief executive officer of GH Research PLC (GHRS).
Where is GH Research PLC headquartered?
GH Research PLC (GHRS) is headquartered in Dublin, Ireland.
What therapeutic areas does GH Research PLC focus on?
GH Research PLC develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.